Joint research for a company-led clinical trial targeting central nervous system injuries
First written in FY2023-Q3. 5 of 11 entries say "Restated". Latest entry: 2026-08-19.
No other company in this theme has enough history to compare yet.
- 2026-08-19AdvancedFinancial results presentation
「Launch of initiatives toward commercialization of KP8031 (chronic cerebral infarction) * Advancing preparations to start a company-sponsored clinical trial」
The company stated that it had begun initiatives toward commercialization of chronic cerebral infarction and moved to the stage of advancing preparations to start a company-sponsored clinical trial. - FY2026-H1AdvancedAnnual report
「Based on progress and results achieved in research on the development of human iPS cell-derived regenerative medicine products for chronic cerebral infarction and other conditions, we extended the term of the joint research agreement with Osaka Medical Center of the National Hospital Organization through 31 March 2029 to promote concrete preparations for company-sponsored clinical trials.」
Based on progress and results in chronic cerebral infarction, cerebral hemorrhage and traumatic central nervous system injury, the company extended its joint research agreement with Osaka Medical Center through 31 March 2029 and is advancing concrete preparations for company-sponsored clinical trials. - FY2025RestatedAnnual report
「For chronic cerebral infarction, chronic cerebral hemorrhage and chronic traumatic central nervous system injuries, we plan to advance preclinical research in cooperation with Osaka Medical Center of the National Hospital Organization, our joint research partner.」
The company continues its policy of advancing preclinical research on chronic cerebral infarction and other conditions in cooperation with Osaka Medical Center. - FY2024RestatedAnnual report
「For the other development pipelines, we are actively advancing joint research with Kitasato Institute and Osaka Medical Center of the National Hospital Organization, which has entered its second year, as well as our own research and development, toward realizing regenerative medicine.」
The company continues joint research with Kitasato Institute and Osaka Medical Center, together with its own research and development. - FY2024-H1RestatedAnnual report
「For the other development pipelines, we are advancing joint research with Kitasato Institute and Osaka Medical Center of the National Hospital Organization, with which we entered into and began joint research agreements in 2023, as well as our own research and development, toward realizing regenerative medicine.」
The company continues to pursue regenerative medicine through joint research with Kitasato Institute and Osaka Medical Center and its own research and development. - FY2024-Q1RestatedAnnual report
「For the other development pipelines, we are advancing joint research with Kitasato Institute and Osaka Medical Center of the National Hospital Organization, with which we entered into and began joint research agreements in 2023, as well as our own research and development, toward realizing regenerative medicine.」
The company continues to pursue regenerative medicine through joint research with Kitasato Institute and Osaka Medical Center and its own research and development. - FY2023RestatedAnnual report
「For the development pipelines for chronic cerebral infarction, chronic cerebral hemorrhage and chronic traumatic brain injury, we also began joint research with Osaka Medical Center of the National Hospital Organization in August 2023 and are advancing research and development toward realizing regenerative medicine.」
The company continues preparations for company-sponsored clinical trials for chronic central nervous system injuries through joint research with Osaka Medical Center. - FY2023-Q3First statedAnnual report
「This joint research is being conducted toward company-sponsored clinical trials of regenerative medicine using human iPS cells for chronic cerebral infarction, cerebral hemorrhage and traumatic central nervous system injuries.」
The company entered into a joint research agreement with Osaka Medical Center of the National Hospital Organization for the period from 31 August 2023 through 31 March 2026.